A comparison of the metabolic effects of captopril and atenolol on glucose, insulin and lipoproteins in patients with mild-to-moderate essential hypertension

被引:0
作者
Maritz, FJ
Weich, HFH
Schoeman, HS
机构
[1] TYGERBERG HOSP,DEPT INTERNAL MED,ENDOCRINOL UNIT,TYGERBERG,W CAPE,SOUTH AFRICA
[2] MED UNIV SO AFRICA,DEPT STAT,ZA-0204 MEDUNSA,SOUTH AFRICA
[3] UNIV STELLENBOSCH,TYGERBERG,SOUTH AFRICA
来源
SOUTH AFRICAN MEDICAL JOURNAL | 1995年 / 85卷 / 12期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The metabolic effects of captopril 25 mg twice daily and atenolol 50 mg daily on glucose, insulin and lipids were compared in 83 otherwise healthy mild-to-moderate hypertensives between the ages of 25 and 60 years in a randomised double-blind trial. Hourly glucose and insulin levels were measured during a 2-hour 75 g oral glucose tolerance test at baseline and after 12 weeks of treatment, Lipid profiles including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, HDL(2), HDL(3), triglycerides, apoprotein (Apo)A(1), ApoB, and Apo(a) were obtained before and after the treatment period. Blood pressure decreased significantly and equivalently in both treatment groups, The glucose and insulin levels and glucose x insulin product at 2 hours after the glucose load increased after 12 weeks of treatment with atenolol compared with the baseline values, but these parameters all decreased after the treatment period with captopril compared with their baseline values. These results indicate an improvement in insulin sensitivity with captopril and a deterioration with atenolol, HDL-cholesterol and HDL, decreased in the atenolol group but increased in the captopril group. We conclude that captopril has more favourable effects than atenolol on glucose, insulin and lipid metabolism in the treatment of mild-to-moderate hypertension.
引用
收藏
页码:1342 / 1345
页数:4
相关论文
共 23 条
[1]  
AMES RP, 1982, J CARDIOVASC PHARM, V4, pS206
[2]   DIABETES IN HYPERTENSIVE WOMEN - AN EFFECT OF ANTIHYPERTENSIVE DRUGS OR THE HYPERTENSIVE STATE PER SE [J].
BENGTSSON, C ;
BLOHME, G ;
LAPIDUS, L ;
LUNDGREN, H .
DIABETIC MEDICINE, 1988, 5 (03) :261-264
[3]  
BUCHANAN T, 1989, CLIN RES, V37, pA127
[4]   CLINICAL REVIEW .26. INSULIN RESISTANCE IN OBESE AND NONOBESE MAN [J].
CARO, JF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :691-695
[5]   INSULIN RESISTANCE IN ESSENTIAL-HYPERTENSION [J].
FERRANNINI, E ;
BUZZIGOLI, G ;
BONADONNA, R ;
GIORICO, MA ;
OLEGGINI, M ;
GRAZIADEI, L ;
PEDRINELLI, R ;
BRANDI, L ;
BEVILACQUA, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (06) :350-357
[6]  
FULLER JH, 1980, LANCET, V1, P1373
[7]   THE OSLO STUDY - CHD RISK-FACTORS, SOCIOECONOMIC INFLUENCES, AND INTERVENTION [J].
LEREN, P ;
HELGELAND, A ;
HJERMANN, I ;
HOLME, I .
AMERICAN HEART JOURNAL, 1983, 106 (05) :1200-1206
[8]   PLASMA-LIPOPROTEIN LEVELS IN TREATED AND UNTREATED HYPERTENSIVE MEN AND WOMEN - THE NATIONAL-HEART-FOUNDATION-OF-AUSTRALIA RISK FACTOR PREVALENCE STUDY [J].
MACMAHON, SW ;
MACDONALD, GJ ;
BLACKET, RB .
ARTERIOSCLEROSIS, 1985, 5 (04) :391-396
[9]  
MURPHY MB, 1982, LANCET, V2, P1293
[10]   METABOLIC EFFECTS OF DILTIAZEM AND ATENOLOL - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND-STUDY WITH PARALLEL GROUPS [J].
POLLARE, T ;
LITHELL, H ;
MORLIN, C ;
PRANTARE, H ;
HVARFNER, A ;
LJUNGHALL, S .
JOURNAL OF HYPERTENSION, 1989, 7 (07) :551-559